Loading...
ATXS logo

Astria Therapeutics, Inc.NasdaqGM:ATXS 株式レポート

時価総額 US$718.1m
株価
n/a
1Y68.0%
7D1.1%
1D0.6%
ポートフォリオ価値
​
表示

Astria Therapeutics, Inc.

NasdaqGM:ATXS 株式レポート

時価総額：US$718.1m

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Astria Therapeutics（ATXS）株式概要

アストリア・セラピューティクス社はバイオ医薬品会社で、米国においてアレルギー性疾患および免疫疾患の治療薬の発見、開発、商業化に従事している。 詳細

ATXS ファンダメンタル分析
スノーフレーク・スコア
評価3/6
将来の成長2/6
過去の実績0/6
財務の健全性6/6
配当金0/6

報酬

当社が推定した公正価値より84.1%で取引されている

収益は年間57.5%増加すると予測されています

リスク分析

収益が 100 万ドル未満 ( $706K )

現在は利益が出ておらず、今後3年間で利益が出る見込みはない


ATXS Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

NEW489,177 members

Join community and earn perks

Gain real feedbackFrom our editorial team, personally. Not silence.
Grow your followingReal investors. The kind who actually invest, not scroll past.
Unlock free accessFree premium subscription for consistent and quality authors.
Learn moreCreate Narrative
IN
Investingwilly
BL
BlackGoat
RO
RockeTeller
AG
Agricola
489,177 investors already sharing narratives
View all narratives

Astria Therapeutics, Inc. 競合他社

価格と性能

株価の高値、安値、推移の概要Astria Therapeutics
過去の株価
現在の株価US$12.58
52週高値US$13.29
52週安値US$3.56
ベータ0.019
1ヶ月の変化-2.86%
3ヶ月変化-0.16%
1年変化67.96%
3年間の変化-8.51%
5年間の変化-35.88%
IPOからの変化-98.39%

最新ニュース

Seeking Alpha • Nov 30

Astria Therapeutics: Updating Target Price, Biocryst Deal Expected To Go Through, Hold

Summary I maintain a hold rating on Astria Therapeutics with an updated $13 target price following Biocryst's announced acquisition, expecting a 90%+ chance of deal closure by Q1 2026. The investment thesis shifts from clinical catalyst to merger arbitrage, with strong strategic rationale for BCRX to acquire ATXS and minimal regulatory or financial barriers anticipated. Navenibart (STAR-0215) is viewed as a best-in-class prophylaxis agent, and the acquisition offers shareholders a liquidity event, mitigating phase 3 and competitive risks. While deal risks exist, they are considered minimal; with limited upside from current prices, I have exited my existing position. Read the full article on Seeking Alpha

Recent updates

Seeking Alpha • Nov 30

Astria Therapeutics: Updating Target Price, Biocryst Deal Expected To Go Through, Hold

Summary I maintain a hold rating on Astria Therapeutics with an updated $13 target price following Biocryst's announced acquisition, expecting a 90%+ chance of deal closure by Q1 2026. The investment thesis shifts from clinical catalyst to merger arbitrage, with strong strategic rationale for BCRX to acquire ATXS and minimal regulatory or financial barriers anticipated. Navenibart (STAR-0215) is viewed as a best-in-class prophylaxis agent, and the acquisition offers shareholders a liquidity event, mitigating phase 3 and competitive risks. While deal risks exist, they are considered minimal; with limited upside from current prices, I have exited my existing position. Read the full article on Seeking Alpha
分析記事 • Jul 08

We're Hopeful That Astria Therapeutics (NASDAQ:ATXS) Will Use Its Cash Wisely

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
分析記事 • Mar 13

We're Hopeful That Astria Therapeutics (NASDAQ:ATXS) Will Use Its Cash Wisely

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Seeking Alpha • Feb 18

Astria Therapeutics: A High-Conviction Bet On HAE

Summary Astria Therapeutics' strong cash position and efficient spending provide a financial runway through mid-2027, reducing dilution risk and supporting pivotal trials for navenibart and STAR-0310. Navenibart, targeting hereditary angioedema, shows promising Phase 1b/2 data with a 90-95% reduction in attack rates, positioning it as a potential best-in-class treatment. STAR-0310, aimed at atopic dermatitis, leverages OX40 inhibition and YTE half-life extension technology, though it faces stiff competition and must prove differentiation. Astria's strategic focus on patient-centric dosing regimens and regulatory strength could reshape treatment landscapes, but clinical and commercial execution remains crucial for success. Read the full article on Seeking Alpha
Seeking Alpha • Nov 27

Astria Therapeutics: Transformative Proof Of Concept Data In Hereditary Angioedema

Summary Astria Therapeutics, Inc.'s STAR-0215 shows 90-96% reduction in HAE attack frequency, with a twice-a-year dosing regimen, positioning it as a transformative therapy. The company has a strong cash balance of $344 million, ensuring a runway until 2027, supporting continued development and trials. Competitive positioning is strong, with STAR-0215 outperforming existing treatments like Takhzyro and Haegarda in both efficacy and dosing convenience. Risks are minimal given the promising data, making ATXS stock a buy due to its excellent data, market potential, and upcoming catalysts. Read the full article on Seeking Alpha
分析記事 • Nov 14

Companies Like Astria Therapeutics (NASDAQ:ATXS) Are In A Position To Invest In Growth

Just because a business does not make any money, does not mean that the stock will go down. Indeed, Astria Therapeutics...
分析記事 • Jul 11

We're Hopeful That Astria Therapeutics (NASDAQ:ATXS) Will Use Its Cash Wisely

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Seeking Alpha • Jun 24

Astria Therapeutics: A Cash-Rich Entrant In An Increasingly Crowded Field

Summary Astria Therapeutics stock has fallen 40% since early 2023, but promising early data for its candidate STAR-0215 in treating HAE is helping drive analyst Buy ratings. ATXS stock has a compound called STAR-0310 in development for an immune disorder, with plans for a Phase 1a study in 2025. Despite positive early data for STAR-0215, competition in the HAE market is fierce and likely to get more crowded with promising new treatments on the horizon. An updated analysis of Astria Therapeutics follows in the paragraphs below. Read the full article on Seeking Alpha
Seeking Alpha • Feb 04

Astria Therapeutics: Too Much Risk, Too Little Reward Despite Near-Term Data Readout

Summary Astria Therapeutics (formerly Catabasis Pharmaceuticals) acquired Quellis Biosciences and its lead program, STAR-0215, for the treatment of hereditary angioedema (HAE) in 2021. The company has successfully completed a Phase 1 study for STAR-0215, demonstrating positive results in terms of safety, tolerability, and efficacy. Astria is now moving forward with a Phase 1b/2 study to establish proof-of-concept for STAR-0215 in HAE patients, with initial results expected in Q1 2024. The promise of HAE data in Q124 appears to have lifted the share price and allowed the company to raise funds. If the promise of upcoming is already baked into the share price, given how far behind the competition Astria is in HAE, and in atopic dermatitis with a second candidate, I would give its stock a "sell" rating. Read the full article on Seeking Alpha
分析記事 • Dec 10

We Think Astria Therapeutics (NASDAQ:ATXS) Can Afford To Drive Business Growth

We can readily understand why investors are attracted to unprofitable companies. For example, although...
分析記事 • Jul 27

We Think Astria Therapeutics (NASDAQ:ATXS) Can Afford To Drive Business Growth

We can readily understand why investors are attracted to unprofitable companies. Indeed, Astria Therapeutics...
分析記事 • Apr 03

We're Not Very Worried About Astria Therapeutics' (NASDAQ:ATXS) Cash Burn Rate

We can readily understand why investors are attracted to unprofitable companies. For example, although...
分析記事 • Nov 30

Here's Why We're Not Too Worried About Astria Therapeutics' (NASDAQ:ATXS) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
分析記事 • Aug 01

We're Hopeful That Astria Therapeutics (NASDAQ:ATXS) Will Use Its Cash Wisely

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Seeking Alpha • Jul 15

Dr. Chris Morabito is the new medical chief of Astria Therapeutics

Astria Therapeutics (NASDAQ:ATXS) names more than 20 years of clinical development experience in rare diseases and other indications Chris Morabito, M.D., as Chief Medical Officer.  Dr. Morabito most recently served as the Chief Medical Officer at Fulcrum Therapeutics.
Seeking Alpha • Jun 30

Catabasis Pharmaceuticals: Transformation Through Quellis Biosciences Acquisition

After edasalonexent's failure last year, Catabasis Pharmaceuticals pivoted to the HAE market through the acquisition of Quellis Biosciences. The acquisition brought QLS-215, a preclinical stage monoclonal antibody with a potentially improved profile compared to prophylactic market leader Takhzyro. Much longer half-life and increased potency could result in less frequent administration and it could also improve efficacy. The HAE market is increasingly competitive with additional promising therapies in development, but if preclinical data of QLS-215 translate well into humans, Catabasis could deliver significant gains in the following years.

株主還元

ATXSUS BiotechsUS 市場
7D1.1%3.7%1.6%
1Y68.0%37.9%21.1%

業界別リターン: ATXS過去 1 年間で37.9 % の収益を上げたUS Biotechs業界を上回りました。

リターン対市場: ATXS過去 1 年間で21.1 % の収益を上げたUS市場を上回りました。

価格変動

Is ATXS's price volatile compared to industry and market?
ATXS volatility
ATXS Average Weekly Movement2.7%
Biotechs Industry Average Movement10.3%
Market Average Movement7.2%
10% most volatile stocks in US Market16.7%
10% least volatile stocks in US Market3.1%

安定した株価: ATXS 、 US市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。

時間の経過による変動: ATXSの 週次ボラティリティ は、過去 1 年間で10%から3%に減少しました。

会社概要

設立従業員CEO（最高経営責任者ウェブサイト
200878Jill Milnewww.astriatx.com

バイオ医薬品企業であるアストリア・セラピューティクス社は、米国においてアレルギー性疾患および免疫疾患治療薬の探索、開発、商業化に取り組んでいる。同社の主要製品候補は、血漿カリクレインのモノクローナル抗体阻害剤であるナベニバートで、遺伝性血管性浮腫の治療薬として第1b/2相臨床試験中です。また、同社はモノクローナル抗体OX40アンタゴニストであるSTAR-0310を開発中であり、皮膚のバリア機能低下とかゆみを伴う免疫疾患であるアトピー性皮膚炎の治療薬として臨床開発中である。同社は以前カタバシス・ファーマシューティカルズ・インクとして知られていたが、2021年9月にアストリア・セラピューティクス・インクに社名を変更した。アストリア・セラピューティクス社は2008年に法人化され、マサチューセッツ州ボストンに本社を置いている。2026年1月23日現在、アストリア・セラピューティクス・インクはバイオクリスト・ファーマシューティカルズ・インクの子会社として活動している。

Astria Therapeutics, Inc. 基礎のまとめ

Astria Therapeutics の収益と売上を時価総額と比較するとどうか。
ATXS 基礎統計学
時価総額US$718.13m
収益（TTM）-US$124.03m
売上高(TTM)US$706.00k
1,017x
P/Sレシオ
-5.8x
PER（株価収益率

ATXS は割高か？

公正価値と評価分析を参照

収益と収入

最新の決算報告書（TTM）に基づく主な収益性統計
ATXS 損益計算書（TTM）
収益US$706.00k
売上原価US$0
売上総利益US$706.00k
その他の費用US$124.74m
収益-US$124.03m

直近の収益報告

Sep 30, 2025

次回決算日

該当なし

一株当たり利益（EPS）-2.17
グロス・マージン100.00%
純利益率-17,567.99%
有利子負債／自己資本比率0%

ATXS の長期的なパフォーマンスは？

過去の実績と比較を見る

企業分析と財務データの現状

データ最終更新日（UTC時間）
企業分析2026/01/27 11:59
終値2026/01/22 00:00
収益2025/09/30
年間収益2024/12/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージデータタイムフレーム米国ソース例
会社財務10年
  • 損益計算書
  • キャッシュ・フロー計算書
  • 貸借対照表
アナリストのコンセンサス予想+プラス3年
  • 予想財務
  • アナリストの目標株価
市場価格30年
  • 株価
  • 配当、分割、措置
所有権10年
  • トップ株主
  • インサイダー取引
マネジメント10年
  • リーダーシップ・チーム
  • 取締役会
主な進展10年
  • 会社からのお知らせ

* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。

分析モデルとスノーフレーク

このレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

Astria Therapeutics, Inc. 2 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。1

アナリスト機関
Jonathan WollebenCitizens JMP Securities, LLC